ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Abstract: TH-OR025

Prognosis of Henoch-Schönlein Purpura Nephritis among Adult and Elderly Patients: Nationwide Cohort Study Based on the Japan Renal Biopsy Registry

Session Information

Category: Glomerular

  • 1005 Clinical Glomerular Disorders


  • Komatsu, Hiroyuki, University of Miyazaki, Miyazaki, Japan
  • Fujimoto, Shouichi, University of Miyazaki, Miyazaki, Japan
  • Sugiyama, Hitoshi, Okayama University Graduate School, Okayama, Japan
  • Sato, Hiroshi, Tohoku University, Sendai, Japan
  • Yokoyama, Hitoshi, Kanazawa Medical University, Ishikawa, Japan

Group or Team Name

  • HSPN study group of J-RBR in Japan

The clinical presentation and prognosis of adult and elderly patients with Henoch-Schönlein purpura nephritis (HSPN) has not been investigated in detail. We therefore surveyed the features and outcomes of HSPN based on nationwide data from the Japan Renal Biopsy Registry (J-RBR).


This multi-center cohort study compared the clinico-pathological parameters at diagnosis, initial therapies and outcomes between 106 adult (age 19 - 64 years), and 46 elderly (age ≥ 65 years) patients with HSPN who were registered in the J-RBR between 2007 and 2012. The primary end-points comprised a 50% increase in serum creatinine (sCr) values or end-stage kidney disease. Factors affecting a decrease in renal function were assessed using a Cox proportional hazards model.


The rates of hypertension, impaired renal function, hypoalbuminemia, and crescentic glomerulonephritis were significantly higher among the elderly, compared with the adult patients. About 80% and 60% of the patients in both groups were respectively treated with corticosteroid and renin-angiotensin system (RAS) inhibitors. Both groups had favorable renal survival rates for nine years (93.6% and 91.4% of the adult and elderly patients, respectively). Significantly more elderly than adult patients developed a 50% increase in sCr during a mean observation period of 3.9 years (21.7% vs. 4.7%, p = 0.012). In addition, significantly fewer elderly than adult patients achieved clinical remission (24% vs. 46%, p = 0.016). Multivariate analysis revealed that advanced age (≥ 65 years) was an independent prognostic factor for a decline in renal function (HR, 6.08; p = 0.018).


The renal prognosis of adult and elderly patients with HSPN was favorable when treated aggressively with corticosteroid and RAS inhibitors. However, the course of renal function should be carefully monitored in patients aged over 65 years.